Founded in 2014, Jingze is a biopharmaceutical company dedicated to the application of cutting-edge biotechnology for innovative R&D and industrialization.
Jingze's core team has successive entrepreneurial success and experience in the research, development, manufacturing and commercialization of several biologics. Focusing on ART(Assisted Reproductive Technology ) and ophthalmology, Jingze has laid out a rich product development pipeline. Currently, there are more than ten projects under development, of which four products are in clinical trials (the fastest one has completed Phase III clinical trial enrollment) and two products are under IND filing.
Currently, Jingze has 3 subsidiaries. Shanghai Jingze technology Co., Ltd. is a state-recognized high-tech enterprise with a modern drug pilot transformation center, which can deliver 1-2 innovative molecules to the process development stage every year. Chengdu Jingze pharmaceutical Co., Ltd. covers an area of 101 mu and has a simultaneous innovative drug development platform and industrialization base, which is responsible for innovative molecule design and development and mature product scale production. Chengdu Jing Runze Gene Technology Co., Ltd. develops next-generation innovative drugs based on a nucleic acid tetrahedral drug delivery platform.
Since its development, Jingze has completed the C round of financing and continues to be favored by many capital market, and many listed companies have become shareholders of the company directly or indirectly.
Jingze , with the philosophy of integrity and innovation first, to create high-quality products for the benefit of eye diseases and infertility patients.
He was the deputy general manager of Tibet Pharmaceutical (600211), the chairman of Chengdu Jinkai and Suzhou Jinmeng, and the head of the biopharmaceutical segment of Salubris (002294).
Led and participated in the development of more than 20 new biologics that have been on the market or entered the clinical trial stage, including 5 first-class new biological drugs.
Led the implementation of a number of major new drug creation projects of the National Health Planning Commission and the Ministry of Science and Technology in the 12th and 13th Five-Year Plans.
Won the First Prize of National Science and Technology Progress 、the First Prize of Sichuan Province Science and Technology Progress and other important awards.
He has been awarded more than ten provincial and municipal honorary titles, such as “Distinguished Expert of High-level Innovation and Entrepreneurship Talents” of Chengdu, “Top Ten Science and Technology Charming Figures of Suzhou” , Model Worker of Suzhou, etc.
